BLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas

被引:140
作者
Urosevic, M [1 ]
Willers, J [1 ]
Mueller, B [1 ]
Kempf, W [1 ]
Burg, G [1 ]
Dummer, R [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, Dermatol Klin, CH-8091 Zurich, Switzerland
关键词
D O I
10.1182/blood.V99.2.609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary cutaneous lymphomas (CLs) constitute a spectrum of diseases characterized by a clonal accumulation of lymphocytes in the skin. Most CLs display a T(h)2 cytokine profile, including expression of interleukin-10 (IL-10). Because the up-regulation of HLA-G, a nonclassical class Ib molecule inducible by IL-10, might account for the immunescape of the malignant clone, HLA-G and IL-10 expression has been investigated in 45 cases of primary CL (10 of B-cell and 35 of T-cell origin) with quantitative polymerase chain reaction (PCR) and immunohistochemistry. HLA-G message was present in all cutaneous B-cell (CBCL) and T-cell (CTCL) lymphomas evaluated. Immunohistochemistry revealed HLA-G protein expression in 23 (51%) of 45 cases (7 of 10 CBCL, 16 of 35 CTCL). While in CBCL mostly indolent types displayed HLA-G positivity, in CTCL HLA-G expression was associated with high-grade histology and advanced stage of the disease. Except for neoplastic and infiltrating lymphocytes, other cells such as macrophages and dendritic cells showed HLA-G immunoreactivity. Furthermore, IL-10 protein expression was demonstrated in 16 (73%) of 22 HLA-G(+) cases, which correlated with HLA-G protein presence (P<.001). HLA-G up-regulation together with IL-10 expression in CL might additionally contribute to the evasion of immunosurveillance and facilitate the transition from low- to high-grade lymphomas. (Blood. 2002;99: 609-617) (C) 2002 by The American Society of Hematology.
引用
收藏
页码:609 / 617
页数:9
相关论文
共 79 条
[11]  
Berger CL, 1998, INT J CANCER, V76, P304, DOI 10.1002/(SICI)1097-0215(19980504)76:3<304::AID-IJC3>3.0.CO
[12]  
2-Z
[13]   The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens [J].
Berger, CL ;
Wang, N ;
Christensen, I ;
Longley, J ;
Heald, P ;
Edelson, RL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (03) :392-397
[14]   Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G [J].
Blaschitz, A ;
Lenfant, F ;
Mallet, V ;
Hartmann, M ;
Bensussan, A ;
Geraghty, DE ;
Le Bouteiller, P ;
Dohr, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (12) :3380-3388
[15]   LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells [J].
Borges, L ;
Cosman, D .
CYTOKINE & GROWTH FACTOR REVIEWS, 2000, 11 (03) :209-217
[16]   Immunohistochemical expression of IL-10 in mycosis fungoides [J].
Buhl, L ;
Sogaard, H .
EXPERIMENTAL DERMATOLOGY, 1997, 6 (04) :195-198
[17]   HLA-G expression: immune privilege for tumour cells? [J].
Cabestre, FA ;
Lefebvre, S ;
Moreau, P ;
Rouas-Freiss, N ;
Dausset, J ;
Carosella, ED ;
Paul, P .
SEMINARS IN CANCER BIOLOGY, 1999, 9 (01) :27-36
[18]  
Cantoni C, 1998, EUR J IMMUNOL, V28, P1980, DOI 10.1002/(SICI)1521-4141(199806)28:06<1980::AID-IMMU1980>3.0.CO
[19]  
2-F
[20]   HLA-G: a tolerance molecule from the major histocompatibility complex [J].
Carosella, ED ;
Rouas-Freiss, N ;
Paul, P ;
Dausset, J .
IMMUNOLOGY TODAY, 1999, 20 (02) :60-62